In September 2023, a clinical laboratory acquisition in Thailand offered an important illustration of how Southeast Asia’s diagnostic industry is evolving.
Innoquest Diagnostics One (Thailand) acquired Lab Plus One, a clinical laboratory business, in a transaction valued at approximately 220 million Thai baht.
The acquisition was not simply about purchasing laboratory equipment or expanding testing capacity.
It reflected a broader investment strategy: building larger diagnostic networks by combining established laboratories, clinical relationships, technical infrastructure and specialised medical expertise.
Five years earlier, private equity firm TPG Capital Asia had completed a much larger transaction, acquiring Healthscope’s Asian pathology operations for A$279 million in August 2018.
That acquisition covered 39 laboratories across Singapore, Malaysia and Vietnam.
Together, these transactions demonstrate that regional investors have committed substantial capital to diagnostic laboratory businesses.
They also raise an important question for Vietnam’s healthcare industry.
If routine laboratory testing can benefit from consolidation, could specialised histopathology services become an even more strategically valuable component of regional diagnostic networks?
The 220 Million Baht Laboratory Acquisition in Thailand
On September 1, 2023, Innoquest Diagnostics One (Thailand) completed its acquisition of the entire business of Lab Plus One Co., Ltd.
Lab Plus One was a Thai clinical diagnostics laboratory business and an indirect subsidiary of Pruksa Holding Public Company Limited.
According to Thai law firm Weerawong, Chinnavat & Partners, which advised the buyer, the transaction value was approximately THB 220 million.
The disclosed acquisition price does not establish the company’s revenue, profitability or valuation multiple. Those details would be necessary to determine whether the transaction represented an attractive financial investment.
Nevertheless, the acquisition is significant because of the buyer’s regional position.
Innoquest belongs to Pathology Asia, a diagnostic laboratory group with operations across multiple Asia-Pacific markets.
By November 2023, Pathology Asia reported a presence in Singapore, Malaysia, Vietnam, the Philippines, Thailand, Indonesia and Australia.
Its business model extends beyond operating individual laboratories. It combines local diagnostic services with access to a broader network of testing technologies, medical expertise and operational infrastructure.
The Thai transaction therefore illustrates a possible strategy for regional expansion: acquire an established local laboratory business rather than build an entirely new operation from the ground up.
An existing laboratory may bring referral relationships, local market knowledge, experienced personnel and established operating processes.
These capabilities can be difficult and time-consuming to reproduce independently.
An Earlier A$279 Million Deal Established a Regional Laboratory Platform
The consolidation of diagnostic laboratories in Southeast Asia did not begin with the Thai acquisition.
On August 17, 2018, TPG Capital Asia completed the acquisition of Australian healthcare company Healthscope’s Asian pathology operations for A$279 million.
The transaction included 39 laboratories operating across Singapore, Malaysia and Vietnam under the Quest Laboratories and Gribbles Pathology brands.
For TPG, the acquisition provided an established regional operating platform rather than a collection of unrelated laboratory assets.
The laboratories already had local clinical relationships, personnel, infrastructure and market presence.
These assets could potentially support future acquisitions, operational integration and expansion into additional diagnostic services.
The transaction also highlighted a fundamental characteristic of the laboratory industry.
Healthcare delivery is largely local, but many of the capabilities supporting laboratory diagnostics can be shared across a network.
Patients typically receive care from local doctors and hospitals.
However, specialised testing, laboratory information systems, procurement, training and certain quality-management functions do not necessarily need to be duplicated at every location.
This combination of local clinical access and centralised technical capability helps explain why diagnostic laboratories can attract regional healthcare investors.
Why Southeast Asia’s Diagnostic Laboratories Are Consolidating
Several structural characteristics make diagnostic laboratories potential candidates for consolidation.
1. Laboratory Infrastructure Requires Significant Investment
Modern diagnostic laboratories depend on equipment, specialised personnel, information systems, quality controls and reliable supply chains.
Advanced testing can require additional expenditure on automation, molecular diagnostic platforms, immunohistochemistry equipment and specialised laboratory facilities.
For smaller operators, these investments may be difficult to justify when testing volumes are limited.
A larger laboratory network may distribute selected infrastructure costs across a broader customer base.
Higher testing volumes can also improve equipment utilisation and potentially reduce the average cost of individual tests.
However, these efficiencies depend on effective specimen logistics, appropriate testing volumes and successful operational integration.
Scale alone does not guarantee lower costs.
2. Existing Clinical Relationships Have Commercial Value
Laboratories do not generate sustainable business solely by purchasing equipment.
They depend on relationships with hospitals, clinics and medical practitioners.
These relationships are built through diagnostic accuracy, dependable turnaround times, clear communication and consistent service.
An established laboratory with trusted clinical relationships may therefore offer an acquirer something that cannot be purchased directly from an equipment supplier.
It provides access to an existing referral network.
For regional investors, this can make acquiring a functioning laboratory more attractive than entering a market without established customers.
Nevertheless, referral relationships are not automatically transferable.
Poor integration, changes in service quality or the departure of key medical professionals can weaken an acquired laboratory’s competitive position.
3. Specialised Testing Can Benefit From Shared Capabilities
Not every laboratory needs to perform every diagnostic test.
Routine clinical chemistry and haematology testing may be conducted close to patients, while more complex investigations may benefit from s